Tivic Health SystemsTIVC
TIVC
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
30% more capital invested
Capital invested by funds: $69.8K [Q3] → $90.7K (+$20.9K) [Q4]
0% more funds holding
Funds holding: 10 [Q3] → 10 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
1.7% less ownership
Funds ownership: 4.53% [Q3] → 2.83% (-1.7%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for TIVC.
Financial journalist opinion
Based on 6 articles about TIVC published over the past 30 days
Neutral
Seeking Alpha
6 days ago
Tivic Health Systems, Inc. (TIVC) Q4 2024 Earnings Call Transcript
Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q4 2024 Results Conference Call March 21, 2025 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Lisa Wolf - Interim Chief Financial Officer Operator Welcome to Tivic Health Systems Year-End 2024 Financial Results and Operational Update Conference Call. This call has been prerecorded and the questions you have submitted in advance will be answered following prepared remarks.
Neutral
Business Wire
6 days ago
Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company's operations. “The important strategic events of the past several months have been nothing short of transformative,” stated Tivic Health Chief Executive Officer, Jennifer Ernst. “We have successfully reshaped the.
Neutral
Business Wire
2 weeks ago
Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its year-end financial results for 2024 via pre-recorded conference call and webcast on Friday, March 21, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID.
Neutral
Business Wire
3 weeks ago
Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today new data that shows personalizing its non-invasive vagus nerve stimulation (ncVNS) method optimized the stimulation's impact on autonomic nervous system activity. Tivic Health believes these findings strongly support its strategy to develop highly personalized neuromodulation devices that can better address inflammatory, cardiac and neurologic disorders compared to c.
Neutral
Business Wire
3 weeks ago
Tivic Health Systems, Inc. Announces Reverse Stock Split
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC) (“Tivic Health” or the “Company), a diversified therapeutics company, announced today that its Board of Directors has declared a 1-for-17 reverse stock split of the Company's issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (“Nasdaq”), and is part of the.
Neutral
Business Wire
3 weeks ago
Tivic Health Files Patent For Optimized Electrical Stimulation of the Vagus Nerve
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, announced today that it has filed a new patent application with the U.S. Patent Office. Patent No. 63,492,402, entitled “Method and Apparatus for Electrical Stimulation of the Vagus Nerve,” expands the claims and protection around the technology in advance of potential U.S. Food &.
Neutral
Business Wire
1 month ago
Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to deve.
Neutral
Business Wire
1 month ago
Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement estab.
Neutral
Business Wire
3 months ago
CEO Letter to Shareholders Issued by Tivic Health
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, today released its annual CEO letter to shareholders. Dear Fellow Shareholders: As we conclude 2024 and look forward to 2025, I'd like to take this opportunity to recap some of the important developments this year and share some of our expectations for 2025. Improvements in Commercial Business: We launched ClearUP 2.0, resulting in improved c.
Neutral
Business Wire
4 months ago
Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS) science and device technology. “This quarter we made significant progress on each of the three prongs of our strategy for delivering shareholder value," st.
Charts implemented using Lightweight Charts™